Crinetics Pharmaceuticals CRNX Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax
Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax.
The official record: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's income (loss) from continuing operations before equity method investments, net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's income (loss) from continuing operations before equity method investments, net of tax?
- Crinetics Pharmaceuticals (CRNX) reported income (loss) from continuing operations before equity method investments, net of tax of -$116.33M in Q4 2025.
- How has Crinetics Pharmaceuticals's income (loss) from continuing operations before equity method investments, net of tax changed year-over-year?
- Crinetics Pharmaceuticals's income (loss) from continuing operations before equity method investments, net of tax decreased by 56.2% year-over-year, from -$74.48M to -$116.33M.
- What is the long-term trend for Crinetics Pharmaceuticals's income (loss) from continuing operations before equity method investments, net of tax?
- Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's income (loss) from continuing operations before equity method investments, net of tax has grown at a 49.1% compound annual growth rate (CAGR), from -$209.33M to -$465.32M.
- What does income (loss) from continuing operations before equity method investments, net of tax mean?
- This metric reflects the net financial result of core business operations after accounting for all operating expenses but before considering equity method investments or income tax impacts. It provides a clear view of the underlying profitability of the company's primary drug development and commercialization activities. Investors use this to evaluate the operational viability of the business model independent of external financial structures.